ProductsDistribution Products

Ruconest

Therapeutic indication:

Treatment of acute angioedema attacks in adults with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency.

  • Composition: Conestat Alfa 2100 U/Vial
  • Pharmaceutical form: Powder for solution for injection
  • Method of administration: Intravenous
  • Manufacturer: Pharming
Ruconest - Product Logo

Join Our Mailing List

Sign up to receive Email updates from Kamada

Latest News

Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability
Mar. 6, 2024